Square Pharmaceuticals (SQURPHARMA) Q2 24/25 earnings summary

Executive summary

• Consolidated net revenue for July–December 2024 rose to Tk. 37.72 billion, up 6.1% year-over-year, with net profit after tax increasing to Tk. 12.70 billion, a 13% rise from the prior year.

• Standalone net revenue for Square Pharmaceuticals PLC was Tk. 29.90 billion, with net profit after tax at Tk. 7.85 billion for the six months ended December 2024.

• Earnings per share (EPS) for the consolidated group reached Tk. 14.32, up from Tk. 12.69 year-over-year; standalone EPS was Tk. 8.85, down from Tk. 10.37.

Financial highlights

• Consolidated gross profit for July–December 2024 was Tk. 17.82 billion, up from Tk. 17.47 billion year-over-year; gross margin remained strong.

• Operating profit for the consolidated group was Tk. 10.99 billion, slightly down from Tk. 11.40 billion year-over-year.

• Net asset value (NAV) per share for the consolidated group increased to Tk. 145.52 from Tk. 142.05; standalone NAV per share was Tk. 117.33.

• Net operating cash flow per share (NOCF) for the consolidated group was Tk. 8.28, down from Tk. 14.37 year-over-year due to absence of one-off insurance and credit collections.

• Total assets for the consolidated group reached Tk. 145.57 billion as of December 31, 2024, up from Tk. 132.64 billion at June 30, 2024.

Outlook and guidance

• Management expects continued business growth, with assets performing as intended and no significant seasonal or cyclical sales variations anticipated.

• No significant post-period events or changes in accounting policies were reported.